A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
Phase of Trial: Phase I/II
Latest Information Update: 23 Jan 2019
At a glance
- Drugs Atezolizumab (Primary) ; Guadecitabine (Primary) ; Rasdegafusp-alfa (Primary) ; Poly ICLC
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Jan 2019 Planned number of patients changed from 78 to 75.
- 14 Jan 2019 Status changed from suspended to recruiting.
- 03 Oct 2018 Status changed from recruiting to suspended.